Licensed from Japan Tobacco in 2004, JTT-705 is trailing torcetrapib by at least two years.
FORBES: Magazine Article
Moreover, there is still a significant chance that neither torcetrapib nor Roche's JTT-705 will prove effective.
The Pfizer drug's closest competitor is Roche's pill, known only by the code numbers JTT-705 and R1658.
According to people who have seen the data from those studies, the effect from JTT-705 was considerably bigger than previously seen.
FORBES: Pfizer's Next Problem
Roche has now run a second set of mid-stage trials on JTT-705.
Previous studies of JTT-705 showed only the 30% boost.
应用推荐
模块上移
模块下移
不移动